Methylprednisolone

Synthetic glucocorticoid with anti-inflammatory and immunosuppressive action

Methylprednisolone is a synthetic glucocorticoid that is structurally closely related to the body's own cortisol and has an anti-inflammatory effect five times more potent than prednisolone. It belongs to the group of corticosteroids and combines pronounced anti-inflammatory, immunosuppressive, antiallergic and antiphlogistic properties. In many countries, methylprednisolone is available under brand names such as Medrol, Solu-Medrol (injection preparation) and numerous generics.

Methylprednisolone is one of the most commonly used corticosteroids in clinical medicine. It is available as a tablet for long-term therapy and as an infusion or injection solution for high-dose pulse therapies. High-dose intravenous methylprednisolone (pulse therapy) is used for severe flares of inflammatory diseases such as multiple sclerosis, lupus erythematosus, vasculitides and after transplantations.

Mechanism of Action

Methylprednisolone, like all glucocorticoids, acts via intracellular glucocorticoid receptors (GR). After diffusion through the cell membrane, it binds to the cytosolic GR, leading to a conformational change and translocation of the hormone-receptor complex into the cell nucleus. In the nucleus, the complex binds to specific DNA sequences (glucocorticoid response elements, GRE) and regulates the transcription of numerous genes.

The anti-inflammatory effect arises from: inhibition of the transcription of pro-inflammatory cytokines (IL-1, IL-2, IL-6, TNF-alpha, interferon-gamma); inhibition of phospholipase A2 (through induction of lipocortins), which reduces the production of arachidonic acid and thereby the formation of prostaglandins, leukotrienes and thromboxane; stabilisation of lysosomal membranes and reduction of vascular permeability; inhibition of migration of leukocytes to sites of inflammation.

The immunosuppressive effect is based on inhibition of T lymphocyte proliferation and cytokine production, reduction of B cell antibody production at high doses, and induction of apoptosis in lymphocytes. Compared to prednisolone, methylprednisolone has a lower mineralocorticoid effect (less sodium and water retention), which makes it more favourable for long-term therapy.

Indications

• Rheumatic diseases: Rheumatoid arthritis, polymyalgia rheumatica, systemic lupus erythematosus (SLE), vasculitides, dermatomyositis
• Neurological diseases: Acute flares of multiple sclerosis (high-dose IV pulse therapy 500 to 1000 mg/day for 3 to 5 days), neuromyelitis optica
• Allergic diseases: Severe allergic reactions, anaphylactic reactions (adjuvant), urticaria, allergic bronchial asthma
• Chronic inflammatory bowel diseases: Crohn's disease and ulcerative colitis during a flare
• Transplant medicine: Rejection prophylaxis and treatment of acute rejection reactions
• Dermatological diseases: Severe eczemas, pemphigus, bullous pemphigoid, erythema multiforme major
• Respiratory diseases: Severe bronchial asthma, COPD exacerbations, sarcoidosis
• Endocrinology: Congenital adrenal hyperplasia, de Quervain thyroiditis
• Haematology: Autoimmune thrombocytopenias, haemolytic anaemias, lymphomas (as part of chemotherapy protocols)

Dosage and Administration

Low-dose long-term therapy (oral): 2 to 16 mg daily, depending on the disease and response; administration in the morning to minimise the effect on the circadian cortisol rhythm. Medium to high doses (oral): 16 to 100 mg daily in acute flares; steroid burst over several weeks with stepwise reduction (tapering). High-dose IV pulse therapy: 500 to 1000 mg daily as a short infusion over 3 to 5 days, e.g. in MS flares or severe vasculitis. Intra-articular: 4 to 80 mg depending on joint size for local inflammation.

Methylprednisolone tablets should be taken after meals or with a little milk to reduce gastrointestinal irritation. Alternatively, gastroprotective agents (proton pump inhibitors) can be prescribed. The daily dose should preferably be taken in the morning to mimic the physiological corticosteroid secretion and minimise sleep disturbances. Corticosteroids should never be discontinued abruptly (risk of adrenal insufficiency); gradual dose reduction is always required.

Side Effects

Short-term side effects (common): Mood swings (euphoria, irritability, insomnia), elevated blood glucose (particularly in diabetics), blood pressure increase, weight gain through increased appetite and water retention, gastrointestinal complaints, susceptibility to infections.

Long-term side effects (dose-dependent):

• Cushing syndrome: Characteristic moon face, central obesity, striae rubrae (red stretch marks), muscle weakness
• Osteoporosis: Through inhibition of osteoblast activity and increased calcium excretion; from 3 months of therapy, osteoporosis prophylaxis (calcium, vitamin D, bisphosphonates) is recommended
• Cataract and glaucoma: Particularly with long-term use
• Skin: Skin atrophy, increased tendency to bruise, impaired wound healing, acne, hypertrichosis
• Adrenal suppression: With prolonged therapy, methylprednisolone suppresses the body's own cortisol production; after discontinuation, temporary adrenal insufficiency may occur
• Cardiovascular: Dyslipidaemia, increased risk of atherosclerosis, hypertension
• Psychiatric: Depressions, anxiety disorders, rarely psychoses at higher doses

Drug Interactions

NSAIDs (ibuprofen, diclofenac, aspirin): Greatly increased risk of gastrointestinal ulcers and bleeding; combination only with concurrent gastroprotective therapy (PPI).

Oral anticoagulants (warfarin, phenprocoumon): Altered efficacy; INR monitoring recommended.

Antidiabetics and insulin: Blood glucose elevation from methylprednisolone requires dose adjustment in diabetics; close blood glucose monitoring.

CYP3A4 inhibitors (ketoconazole, clarithromycin, ritonavir): Elevated methylprednisolone levels through reduced breakdown; toxicity risk increases.

CYP3A4 inducers (rifampicin, carbamazepine, phenytoin): Significantly reduced methylprednisolone levels; potential loss of efficacy; dose increase may be required.

Live vaccines: Contraindicated under methylprednisolone, as attenuated pathogens can cause severe disease under immunosuppression.

Diuretics (hydrochlorothiazide, furosemide): Increased development of potassium deficiency; potassium monitoring recommended.

Muscle relaxants (atracurium): Prolonged neuromuscular blockade possible.

Special Notes

Tapering mandatory: After long-term therapy (more than 2 weeks) and after high-dose cycles, methylprednisolone must be gradually reduced, as the adrenal cortex needs time to resume the body's own cortisol production. Abrupt discontinuation can trigger an acute adrenal crisis with life-threatening consequences.

Infectious diseases: Corticosteroids weaken the immune system and can mask or exacerbate existing infections. Tuberculosis, herpes virus infections (including varicella) and systemic fungal infections can take a severe course under corticosteroid therapy. In varicella-exposed patients who are not immune, prophylaxis should be considered.

Pregnancy: Methylprednisolone crosses the placenta, but less well than dexamethasone, which is why it is preferred in pregnancy when there is a clear indication. In the newborn, a transient adrenal insufficiency may occur. Methylprednisolone passes into breast milk; with high-dose pulse therapies it is recommended to discard breast milk during and until 24 hours after the infusion.

Osteoporosis prophylaxis: With planned long-term therapy (more than 3 months), calcium (1000 to 1500 mg/day), vitamin D (800 to 2000 IU/day) and, in the case of increased fracture risk, bisphosphonates should be prescribed.

Frequently Asked Questions

What is the difference between methylprednisolone and prednisolone?

Methylprednisolone has approximately 25% greater anti-inflammatory potency than prednisolone at an equivalent dose. In addition, methylprednisolone has a lower mineralocorticoid effect, leading to less water retention and sodium accumulation. For this reason, methylprednisolone is often preferred for high-dose pulse therapy, as water and sodium retention is lower than with equipotent prednisolone doses.

Can methylprednisolone be stopped abruptly?

No. Methylprednisolone should never be stopped abruptly, as the adrenal cortex has reduced the body's own cortisol production during therapy. Sudden discontinuation can lead to adrenal insufficiency with symptoms such as weakness, nausea, dizziness, low blood pressure and in severe cases a life-threatening Addisonian crisis. The dose must always be reduced gradually under medical supervision.

Can you do sport while taking methylprednisolone?

Light to moderate physical activity is generally possible and even important (e.g. for osteoporosis prevention), but intense sports or strength training should be coordinated with the treating physician. Corticosteroids can affect muscle strength and endurance; additionally, the risk of injury is increased through muscle weakness and impaired connective tissue healing.

Why does cortisone cause such hunger?

Glucocorticoids such as methylprednisolone activate hunger centres in the hypothalamus and increase the appetite for high-calorie food. At the same time, they raise blood glucose through increased gluconeogenesis. This combination leads to weight gain. Conscious dietary control and regular exercise can counteract this.

References

• Summary of Product Characteristics Medrol (Pfizer), as of 2024
• German Society of Neurology (DGN): Guideline Multiple Sclerosis, 2023
• European League Against Rheumatism (EULAR): Recommendations for Glucocorticoid Therapy in Rheumatoid Arthritis, 2022
• Buttgereit F et al.: Optimised glucocorticoid therapy. Annals of the Rheumatic Diseases, 2005
• Federal Institute for Drugs and Medical Devices (BfArM): Product monograph methylprednisolone